Phase II study of cytarabine in men with docetaxel-refractory, castration-resistant prostate cancer with evaluation of TMPRSS2-ERG and SPINK1 as serum biomarkers.
about
Global gene expression profiling reveals SPINK1 as a potential hepatocellular carcinoma markerThe TMPRSS2:ERG rearrangement, ERG expression, and prostate cancer outcomes: a cohort study and meta-analysisIn silico Prediction of Drug-induced Liver Injury Based on Adverse Drug Reaction Reports.High-throughput cell-based compound screen identifies pinosylvin methyl ether and tanshinone IIA as inhibitors of castration-resistant prostate cancer.Androgen Receptor-CaMKK2 Axis in Prostate Cancer and Bone Microenvironment.
P2860
Phase II study of cytarabine in men with docetaxel-refractory, castration-resistant prostate cancer with evaluation of TMPRSS2-ERG and SPINK1 as serum biomarkers.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
2012年论文
@zh
2012年论文
@zh-cn
name
Phase II study of cytarabine i ...... nd SPINK1 as serum biomarkers.
@en
type
label
Phase II study of cytarabine i ...... nd SPINK1 as serum biomarkers.
@en
prefLabel
Phase II study of cytarabine i ...... nd SPINK1 as serum biomarkers.
@en
P2093
P2860
P1433
P1476
Phase II study of cytarabine i ...... nd SPINK1 as serum biomarkers.
@en
P2093
Ian F Tannock
Jack Groskopf
Jan Jongstra
Jennifer J Knox
John R Day
Laurie Adams
Neesha C Dhani
Srikala S Sridhar
Urban Emmenegger
P2860
P304
P356
10.1111/J.1464-410X.2011.10922.X
P577
2012-02-07T00:00:00Z